{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:59:16Z","timestamp":1793908756123,"version":"4.8.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41577-018-0094-3","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T04:45:36Z","timestamp":1543380336000},"page":"104-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Statins: a viable candidate for host-directed therapy against infectious diseases"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-7990","authenticated-orcid":false,"given":"Suraj P.","family":"Parihar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-2163","authenticated-orcid":false,"given":"Reto","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brombacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"94_CR1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","volume":"29","author":"A Endo","year":"1976","unstructured":"Endo, A., Kuroda, M. & Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinium. J. Antibiot. 29, 1346\u20131348 (1976). This is the first paper to identify statins as potent inhibitors of cholesterol synthesis.","journal-title":"J. Antibiot."},{"key":"94_CR2","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan, E. S. & Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160\u20131164 (2001).","journal-title":"Science"},{"key":"94_CR3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/343425a0","volume":"343","author":"JL Goldstein","year":"1990","unstructured":"Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425\u2013430 (1990).","journal-title":"Nature"},{"key":"94_CR4","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","volume":"6","author":"KR Walley","year":"2014","unstructured":"Walley, K. R. et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl Med. 6, 258ra143 (2014).","journal-title":"Sci. Transl Med."},{"key":"94_CR5","unstructured":"Market Publishers. Statins: World Market Outlook 2011\u20132021 (Visiongain, 2011)."},{"key":"94_CR6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2013.284657","volume":"311","author":"JPA Ioannidis","year":"2014","unstructured":"Ioannidis, J. P. A. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. J. Am. Med. Assoc. 311, 463\u2013464 (2014).","journal-title":"J. Am. Med. Assoc."},{"key":"94_CR7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","volume":"4","author":"MK Jain","year":"2005","unstructured":"Jain, M. K. & Ridker, P. M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977\u2013987 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"94_CR8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1126\/science.272.5262.629","volume":"272","author":"MS Brown","year":"1996","unstructured":"Brown, M. S. & Goldstein, J. L. Heart attacks: gone with the century? Science 272, 629 (1996).","journal-title":"Science"},{"key":"94_CR9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","volume":"6","author":"J Greenwood","year":"2006","unstructured":"Greenwood, J., Steinman, L. & Zamvil, S. S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358\u2013370 (2006). References 7 and 9 are excellent reviews on the basic mechanisms of statin actions and immunomodulatory functions.","journal-title":"Nat. Rev. Immunol."},{"key":"94_CR10","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","volume":"111","author":"U Landmesser","year":"2005","unstructured":"Landmesser, U. et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111, 2356\u20132363 (2005).","journal-title":"Circulation"},{"key":"94_CR11","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","volume":"6","author":"B Kwak","year":"2000","unstructured":"Kwak, B., Mulhaupt, F., Myit, S. & Mach, F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399\u20131402 (2000). This is the first paper to show the inhibitory effect of statins on MHC class II expression and T cell functions.","journal-title":"Nat. Med."},{"key":"94_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao, J. K. & Laufs, U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89\u2013118 (2005).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"94_CR13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/79510","volume":"6","author":"Y Kureishi","year":"2000","unstructured":"Kureishi, Y. et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6, 1004\u20131010 (2000).","journal-title":"Nat. Med."},{"key":"94_CR14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.286.5446.1946","volume":"286","author":"G Mundy","year":"1999","unstructured":"Mundy, G. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286, 1946\u20131949 (1999). This is a unique report that shows that statins promote bone formation by increasing BMP2 gene expression and are therefore a potential treatment for osteoporosis.","journal-title":"Science"},{"key":"94_CR15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker, P. M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175\u20131182 (2009).","journal-title":"Lancet"},{"key":"94_CR16","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature04399","volume":"438","author":"FR Maxfield","year":"2005","unstructured":"Maxfield, F. R. & Tabas, I. Role of cholesterol and lipid organization in disease. Nature 438, 612\u2013621 (2005).","journal-title":"Nature"},{"key":"94_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.virol.2009.03.025","volume":"389","author":"C Rothwell","year":"2009","unstructured":"Rothwell, C. et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389, 8\u201319 (2009).","journal-title":"Virology"},{"key":"94_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.molbiopara.2003.10.002","volume":"133","author":"TJ Pucadyil","year":"2004","unstructured":"Pucadyil, T. J., Tewary, P., Madhubala, R. & Chattopadhyay, A. Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol. Biochem. Parasitol. 133, 145\u2013152 (2004).","journal-title":"Mol. Biochem. Parasitol."},{"key":"94_CR19","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.49.2.518-524.2005","volume":"49","author":"Q Xiong","year":"2005","unstructured":"Xiong, Q. et al. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 49, 518\u2013524 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR20","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1126\/science.288.5471.1647","volume":"288","author":"J Gatfield","year":"2000","unstructured":"Gatfield, J. & Pieters, J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 288, 1647\u20131650 (2000).","journal-title":"Science"},{"key":"94_CR21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1146\/annurev.biochem.68.1.157","volume":"68","author":"PA Edwards","year":"1999","unstructured":"Edwards, P. A. & Ericsson, J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu. Rev. Biochem. 68, 157\u2013185 (1999).","journal-title":"Annu. Rev. Biochem."},{"key":"94_CR22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nrc1751","volume":"5","author":"MF Demierre","year":"2005","unstructured":"Demierre, M. F., Higgins, P. D., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nat. Rev. Cancer 5, 930\u2013942 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"94_CR23","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jit550","volume":"209","author":"SP Parihar","year":"2014","unstructured":"Parihar, S. P. et al. Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 209, 754\u2013763 (2014). This is the first study to demonstrate the underlying mechanisms by which statins control mycobacterial growth in humans and mice.","journal-title":"J. Infect. Dis."},{"key":"94_CR24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075490","volume":"8","author":"SP Parihar","year":"2013","unstructured":"Parihar, S. P. et al. Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting listeria-induced phagosomal escape. PLOS ONE 8, e75490 (2013).","journal-title":"PLOS ONE"},{"key":"94_CR25","volume":"6","author":"SP Parihar","year":"2016","unstructured":"Parihar, S. P., Hartley, M. A., Hurdayal, R., Guler, R. & Brombacher, F. Topical simvastatin as host-directed therapy against severity of cutaneous leishmaniasis in mice. Sci. Rep. 6, 33458 (2016).","journal-title":"Sci. Rep."},{"key":"94_CR26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1084\/jem.20040061","volume":"200","author":"G del Real","year":"2004","unstructured":"del Real, G. et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J. Exp. Med. 200, 541\u2013547 (2004). This is an important report that shows direct inhibition of HIV-1 by statins in chronically infected patients.","journal-title":"J. Exp. Med."},{"key":"94_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000598","volume":"9","author":"M Blanc","year":"2011","unstructured":"Blanc, M. et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLOS Biol. 9, e1000598 (2011).","journal-title":"PLOS Biol."},{"key":"94_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd1719","volume":"4","author":"BK Mueller","year":"2005","unstructured":"Mueller, B. K., Mack, H. & Teusch, N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387\u2013398 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"94_CR29","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1073\/pnas.0508235103","volume":"103","author":"H Das","year":"2006","unstructured":"Das, H. et al. Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc. Natl Acad. Sci. USA 103, 6653\u20136658 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"94_CR30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","volume":"19","author":"BA Hamelin","year":"1998","unstructured":"Hamelin, B. A. & Turgeon, J. Hydrophilicity\/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19, 26\u201337 (1998). This is an excellent review on the pharmacological and pharmacokinetic properties of various statins on the market.","journal-title":"Trends Pharmacol. Sci."},{"key":"94_CR31","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.0508492103","volume":"103","author":"M Arora","year":"2006","unstructured":"Arora, M. et al. Simvastatin promotes Th2-type responses through the induction of the chitinase family member Ym1 in dendritic cells. Proc. Natl Acad. Sci. USA 103, 7777\u20137782 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"94_CR32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAD.0000000000000917","volume":"30","author":"S Elahi","year":"2016","unstructured":"Elahi, S., Weiss, R. H. & Merani, S. Atorvastatin restricts HIV replication in CD4+T cells by upregulation of p21. AIDS 30, 171\u2013183 (2016).","journal-title":"AIDS"},{"key":"94_CR33","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1128\/JVI.02277-15","volume":"90","author":"PT Lange","year":"2016","unstructured":"Lange, P. T. et al. Type I interferon counteracts antiviral effects of statins in the context of gammaherpesvirus infection. J. Virol. 90, 3342\u20133354 (2016).","journal-title":"J. Virol."},{"key":"94_CR34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.45.4.1231-1237.2001","volume":"45","author":"TL Gower","year":"2001","unstructured":"Gower, T. L. & Graham, B. S. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 45, 1231\u20131237 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.antiviral.2013.03.015","volume":"98","author":"LI Ravi","year":"2013","unstructured":"Ravi, L. I. et al. Lovastatin treatment mitigates the pro-inflammatory cytokine response in respiratory syncytial virus infected macrophage cells. Antiviral Res. 98, 332\u2013343 (2013).","journal-title":"Antiviral Res."},{"key":"94_CR36","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/01.CIR.0000109485.79183.81","volume":"109","author":"L Potena","year":"2004","unstructured":"Potena, L. et al. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 109, 532\u2013536 (2004).","journal-title":"Circulation"},{"key":"94_CR37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2006.06.107","volume":"347","author":"S Liu","year":"2006","unstructured":"Liu, S., Rodriguez, A. V. & Tosteson, M. T. Role of simvastatin and methyl-beta-cyclodextrin [corrected] on inhibition of poliovirus infection. Biochem. Biophys. Res. Commun. 347, 51\u201359 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"94_CR38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035788","volume":"7","author":"KA Radigan","year":"2012","unstructured":"Radigan, K. A. et al. The effect of rosuvastatin in a murine model of influenza A infection. PLOS ONE 7, e35788 (2012).","journal-title":"PLOS ONE"},{"key":"94_CR39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejps.2009.07.004","volume":"38","author":"Z Liu","year":"2009","unstructured":"Liu, Z. et al. Evaluation of the efficacy and safety of a statin\/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB\/c mice. Eur. J. Pharm. Sci. 38, 215\u2013223 (2009).","journal-title":"Eur. J. Pharm. Sci."},{"key":"94_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.070","author":"Y Xia","year":"2018","unstructured":"Xia, Y. et al. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell https:\/\/doi.org\/10.1016\/j.cell.2018.08.070 (2018). This is the first paper to show that statins can be a potent adjuvant in vaccines against influenza and cancer immunotherapy.","journal-title":"Cell"},{"key":"94_CR41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1083\/jcb.149.1.167","volume":"149","author":"I Coppens","year":"2000","unstructured":"Coppens, I., Sinai, A. P. & Joiner, K. A. Toxoplasma gondii exploits host low-density lipoprotein receptor-mediated endocytosis for cholesterol acquisition. J. Cell Biol. 149, 167\u2013180 (2000).","journal-title":"J. Cell Biol."},{"key":"94_CR42","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1007\/s00436-015-4618-5","volume":"114","author":"N Dinesh","year":"2015","unstructured":"Dinesh, N., Soumya, N. & Singh, S. Antileishmanial effect of mevastatin is due to interference with sterol metabolism. Parasitol. Res. 114, 3873\u20133883 (2015).","journal-title":"Parasitol. Res."},{"key":"94_CR43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exppara.2013.01.020","volume":"134","author":"CS Kuckelhaus","year":"2013","unstructured":"Kuckelhaus, C. S., Kuckelhaus, S. A., Tosta, C. E. & Muniz-Junqueira, M. I. Pravastatin modulates macrophage functions of Leishmania (L.) amazonensis-infected BALB\/c mice. Exp. Parasitol. 134, 18\u201325 (2013).","journal-title":"Exp. Parasitol."},{"key":"94_CR44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.exppara.2010.12.003","volume":"127","author":"CS Kuckelhaus","year":"2011","unstructured":"Kuckelhaus, C. S., Kuckelhaus, S. A. & Muniz-Junqueira, M. I. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis. Exp. Parasitol. 127, 658\u2013664 (2011).","journal-title":"Exp. Parasitol."},{"key":"94_CR45","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-11-13","volume":"11","author":"JB Souraud","year":"2012","unstructured":"Souraud, J. B. et al. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Malar. J. 11, 13 (2012).","journal-title":"Malar. J."},{"key":"94_CR46","volume":"12","author":"J Dormoi","year":"2013","unstructured":"Dormoi, J. et al. Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model. Malar. J. 12, 302 (2013).","journal-title":"Malar. J."},{"key":"94_CR47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.parint.2015.11.001","volume":"65","author":"AA Othman","year":"2016","unstructured":"Othman, A. A. et al. Atorvastatin and metformin administration modulates experimental Trichinella spiralis infection. Parasitol. Int. 65, 105\u2013112 (2016).","journal-title":"Parasitol. Int."},{"key":"94_CR48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.exppara.2016.05.007","volume":"167","author":"AC Alencar","year":"2016","unstructured":"Alencar, A. C. et al. Simvastatin and artesunate impact the structural organization of adult Schistosoma mansoni in hypercholesterolemic mice. Exp. Parasitol. 167, 115\u2013123 (2016). References 45, 46, 47 and 48 highlight that statins can be used in combination therapies against parasitic diseases.","journal-title":"Exp. Parasitol."},{"key":"94_CR49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.exppara.2017.07.010","volume":"181","author":"N Madbouly Taha","year":"2017","unstructured":"Madbouly Taha, N., Salah A Yousof, H. A., El-Sayed, S. H., Younis, A. I. & Ismail Negm, M. S. Atorvastatin repurposing for the treatment of cryptosporidiosis in experimentally immunosuppressed mice. Exp. Parasitol. 181, 57\u201369 (2017).","journal-title":"Exp. Parasitol."},{"key":"94_CR50","first-page":"e02137","volume":"61","author":"F Gonzalez-Herrera","year":"2017","unstructured":"Gonzalez-Herrera, F. et al. Simvastatin attenuates endothelial activation through 15-epi-lipoxin A4 production in murine chronic chagas cardiomyopathy. Antimicrob. Agents Chemother. 61, e02137\u201316 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1128\/AAC.41.4.850","volume":"41","author":"NX Chin","year":"1997","unstructured":"Chin, N. X., Weitzman, I. & Della-Latta, P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41, 850\u2013852 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR52","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1042\/BST0351529","volume":"35","author":"K Wikhe","year":"2007","unstructured":"Wikhe, K., Westermeyer, C. & Macreadie, I. G. Biological consequences of statins in Candida species and possible implications for human health. Biochem. Soc. Trans. 35, 1529\u20131532 (2007).","journal-title":"Biochem. Soc. Trans."},{"key":"94_CR53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1574-6968.2006.00370.x","volume":"262","author":"IG Macreadie","year":"2006","unstructured":"Macreadie, I. G., Johnson, G., Schlosser, T. & Macreadie, P. I. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol. Lett. 262, 9\u201313 (2006).","journal-title":"FEMS Microbiol. Lett."},{"key":"94_CR54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/13693786.2011.610037","volume":"50","author":"M Tashiro","year":"2012","unstructured":"Tashiro, M. et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. Med. Mycol. 50, 353\u2013360 (2012).","journal-title":"Med. Mycol."},{"key":"94_CR55","volume":"9","author":"SM Leal Jr.","year":"2013","unstructured":"Leal, S. M. Jr. et al. Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum. PLOS Pathog. 9, e1003436 (2013).","journal-title":"PLOS Pathog."},{"key":"94_CR56","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1567-1364.2006.00097.x","volume":"6","author":"A Gyetvai","year":"2006","unstructured":"Gyetvai, A. et al. Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res. 6, 1140\u20131148 (2006).","journal-title":"FEMS Yeast Res."},{"key":"94_CR57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4049\/jimmunol.1102175","volume":"188","author":"GS Deepe Jr","year":"2012","unstructured":"Deepe, G. S. Jr & Buesing, W. R. Deciphering the pathways of death of Histoplasma capsulatum-infected macrophages: implications for the immunopathogenesis of early infection. J. Immunol. 188, 334\u2013344 (2012).","journal-title":"J. Immunol."},{"key":"94_CR58","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.181.5.3524","volume":"181","author":"E Mira","year":"2008","unstructured":"Mira, E. et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J. Immunol. 181, 3524\u20133534 (2008).","journal-title":"J. Immunol."},{"key":"94_CR59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/1369378031000137233","volume":"41","author":"JL Song","year":"2003","unstructured":"Song, J. L., Lyons, C. N., Holleman, S., Oliver, B. G. & White, T. C. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med. Mycol. 41, 417\u2013425 (2003).","journal-title":"Med. Mycol."},{"key":"94_CR60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/13693780701397673","volume":"45","author":"J Qiao","year":"2007","unstructured":"Qiao, J., Kontoyiannis, D. P., Wan, Z., Li, R. & Liu, W. Antifungal activity of statins against Aspergillus species. Med. Mycol. 45, 589\u2013593 (2007).","journal-title":"Med. Mycol."},{"key":"94_CR61","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.chom.2010.10.005","volume":"8","author":"OA Chow","year":"2010","unstructured":"Chow, O. A. et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8, 445\u2013454 (2010). This is an important paper demonstrating that statins promote an extracellular mechanism of killing pathogens.","journal-title":"Cell Host Microbe"},{"key":"94_CR62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1462-5822.2005.00659.x","volume":"8","author":"CF Urban","year":"2006","unstructured":"Urban, C. F., Reichard, U., Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell. Microbiol. 8, 668\u2013676 (2006).","journal-title":"Cell. Microbiol."},{"key":"94_CR63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1099\/0022-1317-51-2-105","volume":"51","author":"JD Nash","year":"2002","unstructured":"Nash, J. D., Burgess, D. S. & Talbert, R. L. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J. Med. Microbiol. 51, 105\u2013109 (2002).","journal-title":"Candida albicans. J. Med. Microbiol."},{"key":"94_CR64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10096-003-0947-x","volume":"22","author":"J Afeltra","year":"2003","unstructured":"Afeltra, J. & Verweij, P. E. Antifungal activity of nonantifungal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 22, 397\u2013407 (2003).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"94_CR65","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1128\/AAC.00192-16","volume":"60","author":"E Hennessy","year":"2016","unstructured":"Hennessy, E., Adams, C., Reen, F. J. & O\u2019Gara, F. Is there potential for repurposing statins as novel antimicrobials? Antimicrob. Agents Chemother. 60, 5111\u20135121 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR66","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/cmi.12279","volume":"16","author":"KA Mattos","year":"2014","unstructured":"Mattos, K. A. et al. Mycobacterium leprae intracellular survival relies on cholesterol accumulation in infected macrophages: a potential target for new drugs for leprosy treatment. Cell. Microbiol. 16, 797\u2013815 (2014).","journal-title":"Cell. Microbiol."},{"key":"94_CR67","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1128\/AAC.01826-13","volume":"58","author":"LS Lobato","year":"2014","unstructured":"Lobato, L. S. et al. Statins increase rifampin mycobactericidal effect. Antimicrob. Agents Chemother. 58, 5766\u20135774 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR68","first-page":"203","volume":"6","author":"WC Liao","year":"2016","unstructured":"Liao, W. C. et al. Statin decreases Helicobacter pylori burden in macrophages by promoting autophagy. Front. Cell. Infect. Microbiol. 6, 203 (2016).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"94_CR69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkn282","volume":"62","author":"E Botelho-Nevers","year":"2008","unstructured":"Botelho-Nevers, E., Espinosa, L., Raoult, D. & Rolain, J. M. Lovastatin, but not pravastatin, limits in vitro infection due to Coxiella burnetii. J. Antimicrob. Chemother. 62, 845\u2013847 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"94_CR70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijantimicag.2008.04.027","volume":"32","author":"E Botelho-Nevers","year":"2008","unstructured":"Botelho-Nevers, E., Rolain, J. M., Espinosa, L. & Raoult, D. Statins limit Rickettsia conorii infection in cells. Int. J. Antimicrob. Agents 32, 344\u2013348 (2008).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"94_CR71","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1128\/IAI.72.2.1036-1042.2004","volume":"72","author":"DM Catron","year":"2004","unstructured":"Catron, D. M. et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infection Immun. 72, 1036\u20131042 (2004).","journal-title":"Infection Immun."},{"key":"94_CR72","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/jac\/dku166","volume":"69","author":"C Skerry","year":"2014","unstructured":"Skerry, C. et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. 69, 2453\u20132457 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"94_CR73","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/jac\/dkw014","volume":"71","author":"NK Dutta","year":"2016","unstructured":"Dutta, N. K. et al. Statin adjunctive therapy shortens the duration of TB treatment in mice. J. Antimicrob. Chemother. 71, 1570\u20131577 (2016). Using preclinical models, references 72 and 73 show that statins increase the efficacy of anti-tuberculosis drugs and reduce the length of tuberculosis treatment.","journal-title":"J. Antimicrob. Chemother."},{"key":"94_CR74","first-page":"4936","volume":"173","author":"MT Montero","year":"2004","unstructured":"Montero, M. T., Matilla, J., Gomez-Mampaso, E. & Lasuncion, M. A. Geranylgeraniol regulates negatively caspase-1 autoprocessing: implication in the Th1 response against Mycobacterium tuberculosis. J. Immunol. 173, 4936\u20134944 (2004).","journal-title":"Mycobacterium tuberculosis. J. Immunol."},{"key":"94_CR75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0021-9150(00)00417-2","volume":"153","author":"MT Montero","year":"2000","unstructured":"Montero, M. T. et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153, 303\u2013313 (2000).","journal-title":"Atherosclerosis"},{"key":"94_CR76","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/08923970902806505","volume":"31","author":"HZ Lu","year":"2009","unstructured":"Lu, H. Z. & Li, B. Q. Effect of HMG-CoA reductase inhibitors on activation of human gammadeltaT cells induced by Mycobacterium tuberculosis antigens. Immunopharmacol. Immunotoxicol. 31, 485\u2013491 (2009).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"94_CR77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1189\/jlb.0409273","volume":"87","author":"D Benati","year":"2010","unstructured":"Benati, D. et al. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J. Leukoc. Biol. 87, 433\u2013442 (2010).","journal-title":"S. aureus. J. Leukoc. Biol."},{"key":"94_CR78","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1164\/rccm.200406-729OC","volume":"171","author":"MB Fessler","year":"2005","unstructured":"Fessler, M. B. et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. Am. J. Respir. Crit. Care Med. 171, 606\u2013615 (2005).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94_CR79","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/eji.201141674","volume":"41","author":"PM Dominguez","year":"2011","unstructured":"Dominguez, P. M., Lopez-Bravo, M., Kalinke, U. & Ardavin, C. Statins inhibit iNOS-mediated microbicidal potential of activated monocyte-derived dendritic cells by an IFN-beta-dependent mechanism. Eur. J. Immunol. 41, 3330\u20133339 (2011).","journal-title":"Eur. J. Immunol."},{"key":"94_CR80","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/AAC.49.9.3959-3962.2005","volume":"49","author":"L Erkkila","year":"2005","unstructured":"Erkkila, L. et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob. Agents Chemother. 49, 3959\u20133962 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"94_CR81","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/01.CIR.0000083367.93022.78","volume":"108","author":"R Dechend","year":"2003","unstructured":"Dechend, R. et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 108, 261\u2013265 (2003).","journal-title":"Circulation"},{"key":"94_CR82","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-3565(24)39169-4","volume":"294","author":"H Ando","year":"2000","unstructured":"Ando, H., Takamura, T., Ota, T., Nagai, Y. & Kobayashi, K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J. Pharmacol. Exp. Ther. 294, 1043\u20131046 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"94_CR83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010928","volume":"5","author":"S Ayyadurai","year":"2010","unstructured":"Ayyadurai, S., Lepidi, H., Nappez, C., Raoult, D. & Drancourt, M. Lovastatin protects against experimental plague in mice. PLOS ONE 5, e10928 (2010).","journal-title":"PLOS ONE"},{"key":"94_CR84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1172\/JCI39843","volume":"120","author":"JW Rosch","year":"2010","unstructured":"Rosch, J. W. et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J. Clin. Invest. 120, 627\u2013635 (2010). This is an important paper showing the mechanism by which statins inhibit pneumococcal infection in mice.","journal-title":"J. Clin. Invest."},{"key":"94_CR85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2180-12-73","volume":"12","author":"AR Boyd","year":"2012","unstructured":"Boyd, A. R., Hinojosa, C. A., Rodriguez, P. J. & Orihuela, C. J. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol. 12, 73 (2012).","journal-title":"BMC Microbiol."},{"key":"94_CR86","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.micinf.2016.03.004","volume":"18","author":"TA Van Laar","year":"2016","unstructured":"Van Laar, T. A. et al. Statins reduce spirochetal burden and modulate immune responses in the C3H\/HeN mouse model of Lyme disease. Microbes Infect. 18, 430\u2013435 (2016).","journal-title":"Microbes Infect."},{"key":"94_CR87","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/138920111798281027","volume":"12","author":"SA McDowell","year":"2011","unstructured":"McDowell, S. A., Ma, Y., Kusano, R. & Akinbi, H. T. Simvastatin is protective during Staphylococcus aureus pneumonia. Curr. Pharm. Biotechnol. 12, 1455\u20131462 (2011).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"94_CR88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cell.2017.10.012","volume":"171","author":"E Garcia-Fernandez","year":"2017","unstructured":"Garcia-Fernandez, E. et al. Membrane microdomain disassembly inhibits MRSA antibiotic resistance. Cell 171, 1354\u20131367 (2017).","journal-title":"Cell"},{"key":"94_CR89","volume":"5","author":"S Thangamani","year":"2015","unstructured":"Thangamani, S. et al. Exploring simvastatin, an antihyperlipidemic drug, as a potential topical antibacterial agent. Sci. Rep. 5, 16407 (2015). This is an important report showing that topical application of statin reduces Staphylococcus spp. biofilms and the growth of drug-resistant strains in skin lesions.","journal-title":"Sci. Rep."},{"key":"94_CR90","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.amjmed.2012.04.011","volume":"125","author":"V Chopra","year":"2012","unstructured":"Chopra, V. et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am. J. Med. 125, 1111\u20131123 (2012).","journal-title":"Am. J. Med."},{"key":"94_CR91","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.mayocp.2017.07.008","volume":"92","author":"J Smit","year":"2017","unstructured":"Smit, J. et al. Statin use and risk of community-acquired Staphylococcus aureus bacteremia: a\u00a0population-based case-control study. Mayo Clin. Proc. 92, 1469\u20131478 (2017).","journal-title":"Mayo Clin. Proc."},{"key":"94_CR92","volume":"8","author":"LE Lopez-Cortes","year":"2013","unstructured":"Lopez-Cortes, L. E. et al. Effect of statin therapy in the outcome of bloodstream infections due to Staphylococcus aureus: a prospective cohort study. PLOS ONE 8, e82958 (2013).","journal-title":"PLOS ONE"},{"key":"94_CR93","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00134-009-1429-0","volume":"35","author":"V Novack","year":"2009","unstructured":"Novack, V. et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med. 35, 1255\u20131260 (2009).","journal-title":"Intensive Care Med."},{"key":"94_CR94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00134-005-2859-y","volume":"32","author":"P Kruger","year":"2006","unstructured":"Kruger, P., Fitzsimmons, K., Cook, D., Jones, M. & Nimmo, G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 32, 75\u201379 (2006). This is an important retrospective cohort study demonstrating a reduction in mortality from bacteraemia in patients receiving statin therapy.","journal-title":"Intensive Care Med."},{"key":"94_CR95","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jama.2013.280031","volume":"310","author":"L Papazian","year":"2013","unstructured":"Papazian, L. et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 310, 1692\u20131700 (2013).","journal-title":"JAMA"},{"key":"94_CR96","doi-asserted-by":"crossref","first-page":"E367","DOI":"10.1503\/cmaj.111017","volume":"184","author":"V Novack","year":"2012","unstructured":"Novack, V. et al. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 184, E367\u2013372 (2012).","journal-title":"CMAJ"},{"key":"94_CR97","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.amjmed.2008.06.030","volume":"121","author":"JD Chalmers","year":"2008","unstructured":"Chalmers, J. D., Singanayagam, A., Murray, M. P. & Hill, A. T. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am. J. Med. 121, 1002\u20131007 (2008).","journal-title":"Am. J. Med."},{"key":"94_CR98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.27.3.325","volume":"27","author":"RG Schlienger","year":"2007","unstructured":"Schlienger, R. G., Fedson, D. S., Jick, S. S., Jick, H. & Meier, C. R. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 27, 325\u2013332 (2007).","journal-title":"Pharmacotherapy"},{"key":"94_CR99","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.38992.565972.7C","volume":"333","author":"SR Majumdar","year":"2006","unstructured":"Majumdar, S. R., McAlister, F. A., Eurich, D. T., Padwal, R. S. & Marrie, T. J. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 333, 999 (2006).","journal-title":"BMJ"},{"key":"94_CR100","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201209-1718OC","volume":"187","author":"P Kruger","year":"2013","unstructured":"Kruger, P. et al. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am. J. Respir. Crit. Care Med. 187, 743\u2013750 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94_CR101","volume":"16","author":"JM Patel","year":"2012","unstructured":"Patel, J. M. et al. Randomized double-blind placebo-controlled trial of 40\u2009mg\/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit. Care 16, R231 (2012). References 100 and 101 are placebo-controlled clinical trials demonstrating that the use of atorvastatin improves survival and reduces disease severity in sepsis.","journal-title":"Crit. Care"},{"key":"94_CR102","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1592\/phco.29.6.621","volume":"29","author":"PP Dobesh","year":"2009","unstructured":"Dobesh, P. P., Klepser, D. G., McGuire, T. R., Morgan, C. W. & Olsen, K. M. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 29, 621\u2013630 (2009).","journal-title":"Pharmacotherapy"},{"key":"94_CR103","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.CCM.0000253397.42079.D5","volume":"35","author":"Y Almog","year":"2007","unstructured":"Almog, Y. et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit. Care Med. 35, 372\u2013378 (2007).","journal-title":"Crit. Care Med."},{"key":"94_CR104","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.297.13.1455","volume":"297","author":"R Gupta","year":"2007","unstructured":"Gupta, R. et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 297, 1455\u20131464 (2007).","journal-title":"JAMA"},{"key":"94_CR105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s15010-011-0190-9","volume":"40","author":"W Nseir","year":"2012","unstructured":"Nseir, W., Mograbi, J., Abu-Elheja, O., Bishara, J. & Assy, N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 40, 41\u201348 (2012).","journal-title":"Infection"},{"key":"94_CR106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010702","volume":"5","author":"L Bjorkhem-Bergman","year":"2010","unstructured":"Bjorkhem-Bergman, L., Bergman, P., Andersson, J. & Lindh, J. D. Statin treatment and mortality in bacterial infections\u2014a systematic review and meta-analysis. PLOS ONE 5, e10702 (2010).","journal-title":"PLOS ONE"},{"key":"94_CR107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00134-005-2743-9","volume":"32","author":"R Fernandez","year":"2006","unstructured":"Fernandez, R., De Pedro, V. J. & Artigas, A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med. 32, 160\u2013164 (2006).","journal-title":"Intensive Care Med."},{"key":"94_CR108","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1001\/archinte.168.19.2081","volume":"168","author":"RW Thomsen","year":"2008","unstructured":"Thomsen, R. W. et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch. Intern. Med. 168, 2081\u20132087 (2008).","journal-title":"Arch. Intern. Med."},{"key":"94_CR109","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00134-014-3418-1","volume":"40","author":"SY Ou","year":"2014","unstructured":"Ou, S. Y. et al. Effect of the use of low and high potency statins and sepsis outcomes. Intensive Care Med. 40, 1509\u20131517 (2014).","journal-title":"Intensive Care Med."},{"key":"94_CR110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/rccm.200810-1584OC","volume":"179","author":"M Shyamsundar","year":"2009","unstructured":"Shyamsundar, M. et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am. J. Respir. Crit. Care Med. 179, 1107\u20131114 (2009). This is a double-blind, placebo-controlled study showing that simvastatin reduces pulmonary inflammation even in healthy humans exposed to inhaled LPS.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"94_CR111","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.chest.2017.05.017","volume":"152","author":"P Bedi","year":"2017","unstructured":"Bedi, P. et al. A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study. Chest 152, 368\u2013378 (2017).","journal-title":"Chest"},{"key":"94_CR112","volume":"18","author":"YD Wan","year":"2014","unstructured":"Wan, Y. D., Sun, T. W., Kan, Q. C., Guan, F. X. & Zhang, S. G. Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies. Crit. Care 18, R71 (2014).","journal-title":"Crit. Care"},{"key":"94_CR113","first-page":"921","volume":"81","author":"G Thomas","year":"2015","unstructured":"Thomas, G. et al. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol. 81, 921\u2013930 (2015).","journal-title":"Minerva Anestesiol."},{"key":"94_CR114","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-017-0349-3","volume":"8","author":"MA Wiewel","year":"2018","unstructured":"Wiewel, M. A. et al. The host response in critically ill sepsis patients on statin therapy: a prospective observational study. Ann. Intensive Care 8, 9 (2018).","journal-title":"Ann. Intensive Care"},{"key":"94_CR115","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/cid\/cis733","volume":"55","author":"EM Mortensen","year":"2012","unstructured":"Mortensen, E. M. et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin. Infect. Dis. 55, 1466\u20131473 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"94_CR116","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1183\/09031936.00162006","volume":"31","author":"EM Mortensen","year":"2008","unstructured":"Mortensen, E. M. et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality\u00a0of subjects hospitalised with pneumonia. Eur. Respir. J. 31, 611\u2013617 (2008).","journal-title":"Eur. Respir. J."},{"key":"94_CR117","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1592\/phco.27.12.1619","volume":"27","author":"EM Mortensen","year":"2007","unstructured":"Mortensen, E. M. et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 27, 1619\u20131626 (2007).","journal-title":"Pharmacotherapy"},{"key":"94_CR118","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/thoraxjnl-2015-207052","volume":"71","author":"CC Lai","year":"2016","unstructured":"Lai, C. C. et al. Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of\u00a0a\u00a0nationally representative cohort. Thorax 71, 646\u2013651 (2016).","journal-title":"Thorax"},{"key":"94_CR119","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.chest.2017.04.170","volume":"152","author":"VY Su","year":"2017","unstructured":"Su, V. Y. et al. Statin use is associated with a lower risk of TB. Chest 152, 598\u2013606 (2017). References 118 and 119 clinically demonstrate the beneficial effects of statins against active tuberculosis.","journal-title":"Chest"},{"key":"94_CR120","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-10-152","volume":"10","author":"GN Forrest","year":"2010","unstructured":"Forrest, G. N., Kopack, A. M. & Perencevich, E. N. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect. Dis. 10, 152 (2010).","journal-title":"BMC Infect. Dis."},{"key":"94_CR121","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MAJ.0b013e31828318e2","volume":"347","author":"JP Magulick","year":"2014","unstructured":"Magulick, J. P. et al. The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. Am. J. Med. Sci. 347, 211\u2013216 (2014).","journal-title":"Am. J. Med. Sci."},{"key":"94_CR122","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13693786.2012.692490","volume":"51","author":"ML Welch","year":"2013","unstructured":"Welch, M. L., Liappis, A. P. & Kan, V. L. Candidemia outcomes not improved with statin use. Med. Mycol. 51, 219\u2013222 (2013).","journal-title":"Med. Mycol."},{"key":"94_CR123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022655","volume":"6","author":"S Jouneau","year":"2011","unstructured":"Jouneau, S. et al. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLOS ONE 6, e22655 (2011).","journal-title":"PLOS ONE"},{"key":"94_CR124","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1111\/j.1439-0507.2010.01957.x","volume":"54","author":"JN Thompson","year":"2011","unstructured":"Thompson, J. N., Huycke, M. M., Greenfield, R. A., Kurdgelashvili, G. & Gentry, C. A. Case-control study of statin prevention of mould infections. Mycoses 54, e481\u2013485 (2011).","journal-title":"Mycoses"},{"key":"94_CR125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/aid.2016.0134","volume":"33","author":"L Calza","year":"2017","unstructured":"Calza, L. et al. Significant decrease in plasma levels of D-dimer, interleukin-8, and interleukin-12 after a 12-month treatment with rosuvastatin in HIV-infected patients under antiretroviral therapy. AIDS Res. Hum. Retroviruses 33, 126\u2013132 (2017).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"94_CR126","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00716-15","volume":"6","author":"DS Fedson","year":"2015","unstructured":"Fedson, D. S., Jacobson, J. R., Rordam, O. M. & Opal, S. M. Treating the host response to ebola virus disease with generic statins and angiotensin receptor blockers. MBio 6, e00716 (2015).","journal-title":"MBio"},{"key":"94_CR127","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jinf.2012.10.016","volume":"65","author":"CJ Montoya","year":"2012","unstructured":"Montoya, C. J. et al. Randomized clinical trial of lovastatin in HIV-infected, HAART naive patients (NCT00721305). J. Infect. 65, 549\u2013558 (2012).","journal-title":"J. Infect."},{"key":"94_CR128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/003655400750045196","volume":"32","author":"SR Penzak","year":"2000","unstructured":"Penzak, S. R. & Chuck, S. K. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand. J. Infect. Dis. 32, 111\u2013123 (2000).","journal-title":"Scand. J. Infect. Dis."},{"key":"94_CR129","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","volume":"115","author":"MJ Feinstein","year":"2015","unstructured":"Feinstein, M. J., Achenbach, C. J., Stone, N. J. & Lloyd-Jones, D. M. A. Systematic review of the usefulness of statin therapy in HIV-infected patients. Am. J. Cardiol. 115, 1760\u20131766 (2015). This is an extensive systematic review evaluating 18 clinical trials of statins that shows that pravastatin, rosuvastatin and pitavastatin have the best safety profiles when coadministered with ART in patients infected with HIV.","journal-title":"Am. J. Cardiol."},{"key":"94_CR130","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1097\/01.aids.0000183517.60384.db","volume":"19","author":"G Moncunill","year":"2005","unstructured":"Moncunill, G. et al. Evaluation of the anti-HIV activity of statins. AIDS 19, 1697\u20131700 (2005).","journal-title":"AIDS"},{"key":"94_CR131","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1097\/QAD.0000000000001219","volume":"30","author":"NT Oliver","year":"2016","unstructured":"Oliver, N. T., Hartman, C. M., Kramer, J. R. & Chiao, E. Y. Statin drugs decrease progression to cirrhosis in HIV\/hepatitis C virus coinfected individuals. AIDS 30, 2469\u20132476 (2016).","journal-title":"AIDS"},{"key":"94_CR132","doi-asserted-by":"crossref","unstructured":"Chang, F. M. et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology (2017).","DOI":"10.1002\/hep.29172"},{"key":"94_CR133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/jir695","volume":"205","author":"ML Vandermeer","year":"2012","unstructured":"Vandermeer, M. L. et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 205, 13\u201319 (2012).","journal-title":"J. Infect. Dis."},{"key":"94_CR134","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0162-3109(00)00272-1","volume":"1","author":"PA Kiener","year":"2001","unstructured":"Kiener, P. A. et al. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol. 1, 105\u2013118 (2001).","journal-title":"Int. Immunopharmacol."},{"key":"94_CR135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2013.12.002","volume":"88","author":"IC Gelissen","year":"2014","unstructured":"Gelissen, I. C. & McLachlan, A. J. The pharmacogenomics of statins. Pharmacol. Res. 88, 99\u2013106 (2014).","journal-title":"Pharmacol. Res."},{"key":"94_CR136","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenom. J. 11, 274\u2013286 (2011).","journal-title":"Pharmacogenom. J."},{"key":"94_CR137","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"SC Group","year":"2008","unstructured":"Group, S. C. et al. SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N. Engl. J. Med. 359, 789\u2013799 (2008).","journal-title":"N. Engl. J. Med."},{"key":"94_CR138","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","volume":"6","author":"MK DeGorter","year":"2013","unstructured":"DeGorter, M. K. et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ. Cardiovasc. Genet. 6, 400\u2013408 (2013). References 136, 137 and 138 identify several polymorphisms associated with the individual variability in responses to statin therapy.","journal-title":"Circ. Cardiovasc. Genet."},{"key":"94_CR139","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","volume":"68","author":"C Kyrklund","year":"2000","unstructured":"Kyrklund, C. et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68, 592\u2013597 (2000).","journal-title":"Clin. Pharmacol. Ther."},{"key":"94_CR140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2012-0033","volume":"28","author":"LK Golightly","year":"2013","unstructured":"Golightly, L. K., Barber, G. R., Barron, M. A. & Page, R. L. 2nd. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability. Drug Metabol. Drug Interact. 28, 49\u201358 (2013).","journal-title":"Drug Metabol. Drug Interact."},{"key":"94_CR141","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2478\/acph-2013-0022","volume":"63","author":"A Causevic-Ramosevac","year":"2013","unstructured":"Causevic-Ramosevac, A. & Semiz, S. Drug interactions with statins. Acta Pharm. 63, 277\u2013293 (2013).","journal-title":"Acta Pharm."},{"key":"94_CR142","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/dmdi.2011.106","volume":"26","author":"S Roques","year":"2011","unstructured":"Roques, S., Lytrivi, M., Rusu, D., Devriendt, J. & De Bels, D. Rhabdomyolysis-induced acute renal failure due to itraconazole and simvastatin association. Drug Metabol. Drug Interact. 26, 79\u201380 (2011).","journal-title":"Drug Metabol. Drug Interact."},{"key":"94_CR143","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","volume":"52","author":"B Chauvin","year":"2013","unstructured":"Chauvin, B., Drouot, S., Barrail-Tran, A. & Taburet, A. M. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin. Pharmacokinet. 52, 815\u2013831 (2013). This is an excellent review summarizing the drug\u2013drug interactions between statins and antiretroviral treatments.","journal-title":"Clin. Pharmacokinet."},{"key":"94_CR144","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(17)30075-9","volume":"4","author":"JA Aberg","year":"2017","unstructured":"Aberg, J. A. et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase\u00a04, multicentre, randomised, double-blind, superiority trial. Lancet HIV 4, e284\u2013e294 (2017).","journal-title":"Lancet HIV"},{"key":"94_CR145","first-page":"59","volume":"19","author":"E Bernal","year":"2017","unstructured":"Bernal, E., Marin, I., Masia, M. & Gutierrez, F. Statins in HIV-infected patients: potential beneficial effects and clinical use. AIDS Rev. 19, 59\u201371 (2017).","journal-title":"AIDS Rev."},{"key":"94_CR146","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/cmaj.140950","volume":"187","author":"DQ Li","year":"2015","unstructured":"Li, D. Q. et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ 187, 174\u2013180 (2015).","journal-title":"CMAJ"},{"key":"94_CR147","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40256-017-0222-7","volume":"17","author":"BS Wiggins","year":"2017","unstructured":"Wiggins, B. S. et al. Recommendations for managing drug-drug interactions with statins and HIV medications. Am. J. Cardiovasc. Drugs 17, 375\u2013389 (2017).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"94_CR148","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1179\/2047773215Y.0000000021","volume":"109","author":"M Canavese","year":"2015","unstructured":"Canavese, M. & Crisanti, A. Vascular endothelial growth factor (VEGF) and lovastatin suppress the inflammatory response to Plasmodium berghei infection and protect against experimental cerebral malaria. Pathog. Glob. Health 109, 266\u2013274 (2015).","journal-title":"Pathog. Glob. Health"},{"key":"94_CR149","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijantimicag.2017.04.005","volume":"49","author":"NQ Ribeiro","year":"2017","unstructured":"Ribeiro, N. Q. et al. Atorvastatin as a promising anticryptococcal agent. Int. J. Antimicrob. Agents 49, 695\u2013702 (2017).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"94_CR150","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.4049\/jimmunol.172.12.7377","volume":"172","author":"M Matsumoto","year":"2004","unstructured":"Matsumoto, M., Einhaus, D., Gold, E. S. & Aderem, A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 172, 7377\u20137384 (2004).","journal-title":"J. Immunol."},{"key":"94_CR151","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef, S. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78\u201384 (2002). This is the first paper to show that statins promote T H 2 cell responses and inhibit T H 1 cell-type immunity.","journal-title":"Nature"},{"key":"94_CR152","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clim.2005.06.014","volume":"117","author":"H Bessler","year":"2005","unstructured":"Bessler, H., Salman, H., Bergman, M., Straussberg, R. & Djaldetti, M. In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin. Immunol. 117, 73\u201377 (2005).","journal-title":"Clin. Immunol."},{"key":"94_CR153","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1189\/jlb.0205064","volume":"79","author":"A Yilmaz","year":"2006","unstructured":"Yilmaz, A. et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 79, 529\u2013538 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"94_CR154","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.1917","volume":"11","author":"R Guler","year":"2015","unstructured":"Guler, R. & Brombacher, F. Host-directed drug therapy for tuberculosis. Nat. Chem. Biol. 11, 748\u2013751 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"94_CR155","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.ATV.0000077220.44620.9B","volume":"23","author":"AF Ayyobi","year":"2003","unstructured":"Ayyobi, A. F. et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 23, 1289\u20131294 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-018-0094-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-018-0094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-018-0094-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T06:29:29Z","timestamp":1775284169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-018-0094-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1038\/s41577-018-0094-3","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"28 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}